These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 8539907)

  • 1. Tolerance induction to islet allografts following infusion of perforin deficient bone marrow.
    Selvaggi G; Inverardi L; Levy RB; Mintz DH; Podack ER; Ricordi C
    Transplant Proc; 1995 Dec; 27(6):3193. PubMed ID: 8539907
    [No Abstract]   [Full Text] [Related]  

  • 2. Survival of islet grafts in perforin-deficient mice.
    Lu X; Ledermann B; Borel JF
    Transplant Proc; 1995 Dec; 27(6):3262-3. PubMed ID: 8539943
    [No Abstract]   [Full Text] [Related]  

  • 3. NK cells promote islet allograft tolerance via a perforin-dependent mechanism.
    Beilke JN; Kuhl NR; Van Kaer L; Gill RG
    Nat Med; 2005 Oct; 11(10):1059-65. PubMed ID: 16155578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.
    Edinger M; Hoffmann P; Ermann J; Drago K; Fathman CG; Strober S; Negrin RS
    Nat Med; 2003 Sep; 9(9):1144-50. PubMed ID: 12925844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A more persistent tolerance to islet allografts through bone marrow transplantation in minimal nonmyeloablative conditioning therapy.
    Lee BW; Lee JI; Oh SH; Ahn YR; Chae HY; Lee MS; Lee MK; Kim KW
    Transplant Proc; 2005 Jun; 37(5):2266-9. PubMed ID: 15964395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rejection of human islets and human HLA-A2.1 transgenic mouse islets by alloreactive human lymphocytes in immunodeficient NOD-scid and NOD-Rag1(null)Prf1(null) mice.
    Banuelos SJ; Shultz LD; Greiner DL; Burzenski LM; Gott B; Lyons BL; Rossini AA; Appel MC
    Clin Immunol; 2004 Sep; 112(3):273-83. PubMed ID: 15308121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nature of tolerance induction to peripheral (extrathymic) islet allografts.
    Coulombe M; Lafferty KJ; Gill RG
    Transplant Proc; 1994 Apr; 26(2):720-1. PubMed ID: 8171624
    [No Abstract]   [Full Text] [Related]  

  • 8. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways.
    Zimmerman Z; Shatry A; Deyev V; Podack E; Mammolenti M; Blazar BR; Yagita H; Levy RB
    Biol Blood Marrow Transplant; 2005 Aug; 11(8):576-86. PubMed ID: 16041307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing the relative role of perforin/granzyme versus Fas/Fas ligand cytotoxic pathways in CD8+ T cell-mediated insulin-dependent diabetes mellitus.
    Kreuwel HT; Morgan DJ; Krahl T; Ko A; Sarvetnick N; Sherman LA
    J Immunol; 1999 Oct; 163(8):4335-41. PubMed ID: 10510373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mixed allogeneic chimerism achieved by lethal and nonlethal conditioning approaches induces donor-specific tolerance to simultaneous islet allografts.
    Li H; Colson YL; Ildstad ST
    Transplantation; 1995 Sep; 60(6):523-9. PubMed ID: 7570945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perforin- and Fas-mediated cytotoxic pathways are not required for allogeneic resistance to bone marrow grafts in mice.
    Baker MB; Podack ER; Levy RB
    Biol Blood Marrow Transplant; 1995 Dec; 1(2):69-73. PubMed ID: 9118294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FK506 inhibits severe graft-versus-host disease without mediating the involvement of perforin and granzyme B.
    Tao HR
    Hokkaido Igaku Zasshi; 1998 May; 73(3):227-37. PubMed ID: 9719949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of tolerance to islet allografts with preoperative donor spleen cell injection and a short course of FK 506 treatment.
    Fukuzaki T; Gotoh M; Monden M; Dono K; Wada H; Tono T; Nagano H; Kanai T; Mori T
    Transplant Proc; 1991 Dec; 23(6):3221-2. PubMed ID: 1721415
    [No Abstract]   [Full Text] [Related]  

  • 14. Veto activity of activated bone marrow does not require perforin and Fas ligand.
    Chrobak P; Gress RE
    Cell Immunol; 2001 Mar; 208(2):80-7. PubMed ID: 11333140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abrogation of graft-versus-host disease following allotransplantation of cytotoxically deficient bone marrow across major histocompatibility barriers.
    Selvaggi G; Inverardi L; Levy RB; Brendel MD; Spielman J; Mintz DH; Podack ER; Ricordi C
    Ann N Y Acad Sci; 1995 Dec; 770():339-44. PubMed ID: 8597370
    [No Abstract]   [Full Text] [Related]  

  • 16. Donor double-negative Treg promote allogeneic mixed chimerism and tolerance.
    He KM; Ma Y; Wang S; Min WP; Zhong R; Jevnikar A; Zhang ZX
    Eur J Immunol; 2007 Dec; 37(12):3455-66. PubMed ID: 18000953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of total lymphoid irradiation (TLI) in bone marrow and organ transplantation.
    Strober S; Gottlieb M; Slavin S; Hoppe R; Grumet FC; Kaplan HS
    Transplant Proc; 1979 Dec; 11(4):1930-3. PubMed ID: 43614
    [No Abstract]   [Full Text] [Related]  

  • 18. T lymphocyte indifference to extrathymic islet allografts.
    Coulombe M; Gill RG
    J Immunol; 1996 Mar; 156(5):1998-2003. PubMed ID: 8596055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host disease.
    Merad M; Hoffmann P; Ranheim E; Slaymaker S; Manz MG; Lira SA; Charo I; Cook DN; Weissman IL; Strober S; Engleman EG
    Nat Med; 2004 May; 10(5):510-7. PubMed ID: 15098028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Durable mixed allogeneic chimerism and tolerance by a nonlethal radiation-based cytoreductive approach.
    Colson YL; Li H; Boggs SS; Patrene KD; Johnson PC; Ildstad ST
    J Immunol; 1996 Oct; 157(7):2820-9. PubMed ID: 8816385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.